Abstract
Clinical trials with hematopoietic growth factors (granulocyte-macrophage colony-stimulating factor [GM-CSF], granulocyte colony-stimulating factor [G-CSF], interleukin-3, or erythropoietin) have been performed on patients with myelodysplastic syndromes. Absolute neutrophil counts can be readily raised to within the normal range by treatment with GM-CSF or G-CSF. Increases in platelets and hemoglobin have been reported after treatment with interleukin-3 and erythropoietin, respectively. Cytogenetic and molecular genetic analyses have demonstrated that both normal and malignant precursor cells are stimulated by cytokine therapy.
MeSH terms
-
Cytarabine / administration & dosage
-
Cytarabine / therapeutic use
-
Drug Synergism
-
Erythropoietin / therapeutic use
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
-
Hematopoietic Cell Growth Factors / therapeutic use*
-
Humans
-
Interleukin-3 / therapeutic use
-
Myelodysplastic Syndromes / drug therapy*
-
Myelodysplastic Syndromes / pathology
Substances
-
Hematopoietic Cell Growth Factors
-
Interleukin-3
-
Cytarabine
-
Erythropoietin
-
Granulocyte Colony-Stimulating Factor
-
Granulocyte-Macrophage Colony-Stimulating Factor